Quince Therapeutics Inc (QNCX) Stock Price, Quote & News

Company Profile

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an aut...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 910 5717

Website: www.quincetx.com

Address:

611 Gateway Boulevard, Suite 273, South San Francisco, United States

BonprixUltimateGuardians May. 13 at 8:46 PM

$ROLR $QNCX $LTBR $CYN $SWKS respect

0 · Reply

tradingTrice May. 13 at 7:11 PM

$QNCX Question: does anyone expect news before the stakeholder meeting. Im not, but curious to the reasoning behind why someone may...Maybe Im missing something. In my mind, a merger candidate would want the stock much higher before signing a deal. So there must be a vote which is why they also brought on the previous board member and that's where the split approval comes in. Im sure theres a candidate already but I don't see how we'd know before meeting. But I'm no expert at all... open to feedback from someone more knowledgeable...thanks...

2 · Reply

Xgurule May. 13 at 6:36 PM

$QNCX today $SRXH, but soon us 🙏🏻

0 · Reply

lorenaw May. 13 at 6:10 PM

$QNCX sooon 💰💰💰

1 · Reply

Makethatmoney99 May. 13 at 5:42 PM

$QNCX still here

0 · Reply

RichardCraniumWozEre May. 13 at 4:43 PM

$QNCX 🧘🏽‍♂️

0 · Reply

_BUBBLES_ May. 13 at 3:50 PM

$QNCX Matter of time..

0 · Reply

makesomemoneybro123 May. 13 at 1:21 PM

$QNCX trash... Not moving at all

1 · Reply

lorenaw May. 13 at 9:20 AM

$QNCX $WOK $DXF lets go

0 · Reply

RichardCraniumWozEre May. 13 at 5:56 AM

$QNCX 🧘🏽‍♂️

1 · Reply

Largest borrow rate increases among liquid names

BHP CHPT PCT SPIR YPF

2026-04-16T14:15:30.000Z - 27 days ago

Largest borrow rate increases among liquid names

ALTO INDA MRLN RUM VWAV WRD

2026-04-10T23:53:15.000Z - 4 weeks ago

Quince Therapeutics trading halted, news pending

2026-04-10T12:45:57.000Z - 4 weeks ago

Largest borrow rate increases among liquid names

BBD BBDO BKLN BYND CBRL CGC MSTX

2026-03-30T12:54:26.000Z - 6 weeks ago

Quince Therapeutics settles $16.4M of debt

Mar 30, 2026, 8:30 AM EDT - 6 weeks ago

Quince Therapeutics Settles Approximately $16.4 Million of Debt

2026-03-23T17:35:47.000Z - 7 weeks ago

Quince Therapeutics options imply 68.7% move in share price post-earnings

2026-02-10T12:58:18.000Z - 3 months ago

Why Is Quince Therapeutics Stock (QNCX) Up Today?

Feb 9, 2026, 4:05 PM EST - 3 months ago

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives

Jan 29, 2026, 3:10 PM EST - 3 months ago

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia

Jan 28, 2026, 4:05 PM EST - 3 months ago

Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting

Dec 15, 2025, 8:00 AM EST - 5 months ago

Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia

Dec 10, 2025, 4:05 PM EST - 5 months ago

Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders

Dec 3, 2025, 10:30 AM EST - 5 months ago

Quince Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 8:00 AM EST - 6 months ago

Quince Therapeutics to Participate at Investor Events in December 2025

Nov 12, 2025, 4:05 PM EST - 6 months ago

Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 4:05 PM EST - 6 months ago

Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Oct 9, 2025, 4:05 PM EDT - 7 months ago

Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting

Oct 2, 2025, 10:00 AM EDT - 7 months ago

Quince Therapeutics Transcript: Investor Day 2025

Sep 25, 2025, 4:05 PM EDT - 8 months ago

Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study

Sep 11, 2025, 4:05 PM EDT - 8 months ago

Quince Therapeutics to Host Virtual Investor Day on October 2, 2025

Sep 5, 2025, 7:00 AM EDT - 8 months ago

Quince Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 4:05 PM EDT - 9 months ago

Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 11, 2025, 4:05 PM EDT - 9 months ago

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 8:00 AM EDT - 9 months ago

Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

OPCH

Jul 16, 2025, 8:00 AM EDT - 10 months ago

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Jul 10, 2025, 4:05 PM EDT - 10 months ago

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

Jun 25, 2025, 4:05 PM EDT - 11 months ago

Quince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research Conference

Jun 18, 2025, 4:05 PM EDT - 11 months ago

Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities

Jun 12, 2025, 5:15 PM EDT - 11 months ago

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

Jun 3, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

May 13, 2025, 8:00 AM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

May 7, 2025, 3:30 PM EDT - 1 year ago

Quince Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

Apr 30, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at Citizens Life Sciences Conference

Apr 3, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

Mar 24, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

Feb 12, 2025, 2:00 PM EST - 1 year ago

Quince Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 7, 2025, 10:00 AM EST - 1 year ago

Quince Therapeutics Transcript: Investor Update

Feb 7, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Feb 5, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

Jan 28, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Jan 27, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

Jan 23, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

Nov 13, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

Nov 11, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

Oct 30, 2024, 3:00 PM EDT - 1 year ago

Quince Therapeutics Transcript: The ThinkEquity Conference 2024

Oct 29, 2024, 6:30 PM EDT - 1 year ago

Quince Therapeutics Transcript: LD Micro Main Event XVII

Oct 14, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Participate at Upcoming Investor Conferences

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Jun 25, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

Jun 3, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System

May 13, 2024, 1:30 PM EDT - 2 years ago

Quince Therapeutics Transcript: The Citizens JMP Life Sciences Conference

May 13, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

May 6, 2024, 4:05 PM EDT - 2 years ago

Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results

Mar 26, 2024, 4:00 PM EDT - 2 years ago

Quince Therapeutics Transcript: Study Update

Feb 22, 2024, 7:00 AM EST - 2 years ago

Quince Therapeutics Launches Scientific Advisory Board

Feb 15, 2024, 7:00 AM EST - 2 years ago

Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

Feb 7, 2024, 4:05 PM EST - 2 years ago

Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 7, 2024, 4:30 PM EST - 2 years ago

Quince Therapeutics Transcript: 7th Annual Neuroscience Innovation Forum

Jan 4, 2024, 4:05 PM EST - 2 years ago

Quince Therapeutics to Participate at Investor Events in January 2024

Jan 2, 2024, 6:00 PM EST - 2 years ago

Quince Therapeutics Transcript: M&A Announcement

Oct 23, 2023, 7:00 AM EDT - 2 years ago

Quince Therapeutics Completes Acquisition of EryDel S.p.A.

Sep 28, 2023, 4:05 PM EDT - 2 years ago

U.S. FDA Partial Clinical Hold Lifted on IND for EryDel's Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Quince Therapeutics Appoints Dr. Charles S. Ryan as President

BonprixUltimateGuardians May. 13 at 8:46 PM

$ROLR $QNCX $LTBR $CYN $SWKS respect

0 · Reply

tradingTrice May. 13 at 7:11 PM

2 · Reply

Xgurule May. 13 at 6:36 PM

$QNCX today $SRXH, but soon us 🙏🏻

0 · Reply

lorenaw May. 13 at 6:10 PM

$QNCX sooon 💰💰💰

1 · Reply

Makethatmoney99 May. 13 at 5:42 PM

$QNCX still here

0 · Reply

RichardCraniumWozEre May. 13 at 4:43 PM

$QNCX 🧘🏽‍♂️

0 · Reply

_BUBBLES_ May. 13 at 3:50 PM

$QNCX Matter of time..

0 · Reply

makesomemoneybro123 May. 13 at 1:21 PM

$QNCX trash... Not moving at all

1 · Reply

lorenaw May. 13 at 9:20 AM

$QNCX $WOK $DXF lets go

0 · Reply

RichardCraniumWozEre May. 13 at 5:56 AM

$QNCX 🧘🏽‍♂️

1 · Reply

lorenaw May. 13 at 12:23 AM

$QNCX patient everyone will get our turn again k💰💰💰

1 · Reply

WUXIANLONG May. 13 at 12:02 AM

$QNCX would flipping between 1.22 and 1.26 everyday work? 😂

1 · Reply

CheckingMorons May. 12 at 10:03 PM

$QNCX the routine is the same : drops during the day , pumps before close - no SEC files submitted back down to during market price . Pm goes up a bit then again no news it will flatline whole day .

0 · Reply

tradingTrice May. 12 at 8:08 PM

$QNCX got beat up in other stocks today but made some profit back to add to this... My precious Qncx ❤️ OAN: they need to hurry the heck up and tell us something already...

0 · Reply

WUXIANLONG May. 12 at 6:22 PM

$QNCX Only bullish thing right now is that someone is keying in huge buys at 1.2 every single day

0 · Reply

CheckingMorons May. 12 at 5:12 PM

$QNCX forgot about this lol other stocks bring me more money but still have shares here . Went short on intel at 125 exit at 117 , 3k profit

1 · Reply

Xgurule May. 12 at 5:09 PM

$QNCX one more week I can add a bit more, looking for 10k shares flat that should get me out of this solar loan if we take off 😅🤣

0 · Reply

AlienTrador May. 12 at 5:00 PM

$QNCX poopetb

0 · Reply

_BUBBLES_ May. 12 at 4:43 PM

$QNCX This will likely ride between 1.18-1.28 this week.. low volume, not much happening.. and then, that’s when shit happens🚀 however much $ you make or lose here depends on how patient you are. A rip to press $2 is inevitable.. don’t sell if you don’t have to👍🏼

0 · Reply

WUXIANLONG May. 12 at 4:36 PM

$QNCX 😴😴😴

0 · Reply

_BUBBLES_ May. 12 at 4:09 PM

$QNCX

0 · Reply

bourock May. 12 at 1:48 PM

$QNCX it feels like they just dont care about the stock price as long as its above $1. Since all the insiders and insttutions locked in they will just move with merger in a time but who knows when.

0 · Reply

Market Cap	20.21M
Revenue (ttm)	0.00
Net Income (ttm)	-83.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-0.50

Volume	503,899
Avg Vol	6,387,522
Day's Range	N/A - N/A
Shares Out	16.30M
Stochastic %K	50%
Beta	1.45
Analysts	Hold
Price Target	$6.50